&Partners’s GSK GSK Stock Holding History

&Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Buy	62,755 +2,640	+4%	+$140K	0.01%	770
2026 Q1	$3.31M	Sell	60,115 -33,190	-36%	-$1.8M	0.02%	689
2025 Q4	$4.58M	Sell	93,305 -2,485	-3%	-$116K	0.02%	525
2025 Q3	$4.13M	Buy	95,790 +7,526	+9%	+$294K	0.03%	484
2025 Q2	$3.39M	Buy	88,264 +49,338	+127%	+$1.89M	0.03%	474
2025 Q1	$1.51M	Buy	38,926 +273	+0.7%	+$9.99K	0.02%	648
2024 Q4	$1.3M	Buy	38,653 +15,441	+67%	+$556K	0.02%	663
2024 Q3	$936K	Buy	23,212 +7,336	+46%	+$300K	0.02%	591
2024 Q2	$611K	Buy	15,876 +9,077	+134%	+$382K	0.03%	476
2024 Q1	$299K	Buy	+6,799	New	+$280K	0.04%	365

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

&Partners's GSK Position: Q2 2026 in Review

&Partners increased its GSK (GSK) stake by 4.4% in Q2 2026, buying an estimated $140K and bringing the position to 62,755 shares worth $3.29M. The position accounts for 0.01% of the portfolio, ranked #770.

&Partners first reported a position in GSK in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.58M in Q4 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

&Partners held 62,755 shares of GSK worth $3.29M as of Q2 2026.
&Partners bought 2,640 GSK shares in Q2 2026, an estimated $140K.
GSK made up 0.01% of &Partners's portfolio in Q2 2026, its #770 holding.
&Partners first reported a position in GSK in Q1 2024 and has held it in 10 quarters since.
&Partners's GSK position peaked at $4.58M in Q4 2025.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.